Penumbra Q1 Revenue Climbs 15.6% to $374.8M, EPS Misses Estimates
PEN•Penumbra posted Q1 net income of $32.6 million and EPS of $0.82, missing analyst projections of $1.11 per share. Revenue rose 15.6% to $374.8 million, gross margin improved 1.0 point to 67.6%, while guidance was withdrawn due to pending Boston Scientific acquisition.
1. Q1 Financial Results
In Q1 2026, Penumbra reported net income of $32.6 million, or $0.82 per diluted share, below the consensus of $1.11. Total revenue reached $374.8 million, up 15.6% year over year, while gross profit margin expanded to 67.6%.
2. Segment Performance
Global thrombectomy sales rose 12.1% to $253.9 million, and embolization and access revenue increased 23.8% to $120.8 million. Operating expenses totaled $215.2 million, including $22.4 million in R&D and $9.4 million of acquisition-related costs.
3. Acquisition Impact and Guidance
The company suspended full-year financial guidance and conference calls due to the pending Boston Scientific acquisition, citing potential regulatory and integration uncertainties. Management highlighted acquisition-related expenses as a factor in first-quarter operating results.
